Undisclosed antiretroviral drug use in Botswana

Year: 2018

Type: article

Abstract: : Among 3596 HIV-positive participants enrolled in the Botswana Combination Prevention Project who self-reported no prior antiretroviral (ARV) therapy use and were tested for viral load (n = 951; 27% of all participants), 136 (14%) had HIV-1 RNA less than 400 copies/ml. ARV drugs were detected in 52 (39%) of 134 participants tested. Adjusting for undisclosed ARV use increased the overall estimate of virally suppressed individuals on ARV therapy by 1.4% from 70.2 to 71.6%.

Source: AIDS

DOI: 10.1097/qad.0000000000001862

Institutions: Harvard University, Botswana Harvard AIDS Institute Partnership, Massachusetts General Hospital, Ministry of Health, Brigham and Women's Hospital, Johns Hopkins Hospital

Language: English

Topic: HIV/AIDS Research and Interventions

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: U.S. President’s Emergency Plan for AIDS Relief, Wellcome Trust, Centers for Disease Control and Prevention, National Institute of Allergy and Infectious Diseases, Fogarty International Center

Awards: G1857082937, G2383610615, IMPACT EVALUATION OF COMBINATION HIV PREVENTION INTERVENTIONS IN BOTSWANA, Sub-Saharan African Network for TB/HIV research Excellence (SANTHE), GH16-002, BOTSWANA: IMPACT EVALUATION OF COMBINATION HIV PREVENTION INTERVENTIONS

OpenAlex ID: W2804260685